Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues

Name: Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues (English version)
SKU: 123037

Dey, Aiyesha; Heese, Jonas; Srinivasan, Suraj; Lobb, Annelena

Product #:123037

Supplier:Harvard Business School

Discipline:Accounting

Setting:United States

Details:Case (PDF) • 29 pages • 2022-10-25 (Rev: 2023-05-09)

Subjects:

Finance and investing Accounting

Geography:

United States North America

Your Price:

$12.40

Purchase this material with a free Educator Account and enjoy more benefits:

Free Educator Copy
Free Teaching Notes
Build your coursepack
Discounted academic price

Ginkgo Bioworks, a synthetic biology company based in Boston, Massachusetts, faced divergent views on its revenue possibilities and accounting practices. After a report emerged accusing it of fraudulent accounting and lack of innovation, its share price plunged. But some investors saw this as a buying opportunity and still believed in Ginkgo's prospects. Who was right?